Trial Profile

A pharmacokinetic study with an integrated food effect arm to assess the safety, tolerability and QTcF interval following different strengths of COMP360 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Depression; Depressive disorders
Focus Adverse reactions
Acronyms COMP 101
Sponsors COMPASS Pathways

Most Recent Events

04 Jan 2022 According to a COMPASS Pathways media release, results from this trial were peer-reviewed and published in The Journal of Psychopharmacology.
04 Jan 2022 Results published in the COMPASS Pathways Media Release.
03 Jun 2021 According to a COMPASS Pathways media release, results from this trial will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com